Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)

To facilitate the achieving of the goal of “eliminating viral hepatitis as a major public health threat by 2030” set by the World Health Organization, the Chinese Society of Hepatology together with the Chinese Society of Infectious Diseases (both are branches of the Chinese Medical Association) org...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Hong, Wang, Fusheng, Li, Taisheng, Xu, Xiaoyuan, Sun, Yameng, Nan, Yuemin, Wang, Guiqiang, Hou, Jinlin, Duan, Zhongping, Wei, Lai, Jia, Jidong, Zhuang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2023
Materias:
Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500285/
https://www.ncbi.nlm.nih.gov/pubmed/37719965
http://dx.doi.org/10.14218/JCTH.2023.00320
Descripción
Sumario:To facilitate the achieving of the goal of “eliminating viral hepatitis as a major public health threat by 2030” set by the World Health Organization, the Chinese Society of Hepatology together with the Chinese Society of Infectious Diseases (both are branches of the Chinese Medical Association) organized a panel of experts and updated the guidelines for prevention and treatment of chronic hepatitis B in China (version 2022). With the support of available evidence, this revision of the guidelines focuses on active prevention, large scale testing, and expansion of therapeutic indication of chronic hepatitis B with the aim of reducing the hepatitis B related disease burden.

Ejemplares similares